NCT03065062 2026-02-13Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid TumorsDana-Farber Cancer InstitutePhase 1 Suspended75 enrolled
NCT05226871 2025-11-25Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) StudiesPfizerPhase 2 Active not recruiting35 enrolled